Therapies for multiple myeloma have evolved very rapidly over the past several years with a significant improvement in outcomes. However, access and availability of drugs remain variable and dictated by regional approval and reimbursement strategies. Consequently, practice patterns are variable and patient access is unequal. Given the rapidly accumulating data and available options, treatment decisions are not straightforward. To combat this disparity, the IMS has started the Therapeutic Map (TMAP) initiative.
TMAP will be a web program that will provide region/country-specific guidelines to help hematologists and oncologists in the care of multiple myeloma patients, by providing the user with availability and coverage information in each region or country.
The IMS is currently collecting data for select countries and has started programming the application. TMAP is expected to launch in 2024.
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
